Literature DB >> 29563615

When worlds collide: Th17 and Treg cells in cancer and autoimmunity.

Hannah M Knochelmann1,2, Connor J Dwyer3,4, Stefanie R Bailey3,4, Sierra M Amaya3,4, Dirk M Elston4, Joni M Mazza-McCrann4, Chrystal M Paulos5,6.   

Abstract

The balance between Th17 cells and regulatory T cells (Tregs) has emerged as a prominent factor in regulating autoimmunity and cancer. Th17 cells are vital for host defense against pathogens but have also been implicated in causing autoimmune disorders and cancer, though their role in carcinogenesis is less well understood. Tregs are required for self-tolerance and defense against autoimmunity and often correlate with cancer progression. This review addresses the importance of a functional homeostasis between these two subsets in health and the consequences of its disruption when these forces collide in disease. Importantly, we discuss the ability of Th17 cells to mediate cancer regression in immunotherapy, including adoptive transfer and checkpoint blockade therapy, and the therapeutic possibilities of purposefully offsetting the Th17/Treg balance to treat patients with cancer as well as those with autoimmune diseases.

Entities:  

Keywords:  Th17; Treg; autoimmunity; cancer; immunotherapy

Mesh:

Year:  2018        PMID: 29563615      PMCID: PMC6068176          DOI: 10.1038/s41423-018-0004-4

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  212 in total

1.  Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5.

Authors:  Xiang-Ping Yang; Kamran Ghoreschi; Scott M Steward-Tharp; Jaime Rodriguez-Canales; Jinfang Zhu; John R Grainger; Kiyoshi Hirahara; Hong-Wei Sun; Lai Wei; Golnaz Vahedi; Yuka Kanno; John J O'Shea; Arian Laurence
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

Review 2.  Immunoregulatory T-cell pathways.

Authors:  D R Green; P M Flood; R K Gershon
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

Review 3.  New insights of T cells in the pathogenesis of psoriasis.

Authors:  Yihua Cai; Chris Fleming; Jun Yan
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

4.  Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience.

Authors:  Dandan Wang; Huayong Zhang; Jun Liang; Xia Li; Xuebing Feng; Hong Wang; Bingzhu Hua; Bujun Liu; Liwei Lu; Gary S Gilkeson; Richard M Silver; Wanjun Chen; Songtao Shi; Lingyun Sun
Journal:  Cell Transplant       Date:  2013       Impact factor: 4.064

5.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Douglas C Palmer; Claudia Wrzesinski; Keith Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

6.  A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells.

Authors:  Derese Getnet; Joseph F Grosso; Monica V Goldberg; Timothy J Harris; Hung-Rong Yen; Tullia C Bruno; Nicholas M Durham; Edward L Hipkiss; Kristin J Pyle; Satoshi Wada; Fan Pan; Drew M Pardoll; Charles G Drake
Journal:  Mol Immunol       Date:  2010-03-11       Impact factor: 4.407

Review 7.  The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings.

Authors:  David A Martin; Jennifer E Towne; Gregory Kricorian; Paul Klekotka; Johann E Gudjonsson; James G Krueger; Chris B Russell
Journal:  J Invest Dermatol       Date:  2012-06-07       Impact factor: 8.551

8.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.

Authors:  T Takahashi; Y Kuniyasu; M Toda; N Sakaguchi; M Itoh; M Iwata; J Shimizu; S Sakaguchi
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

9.  Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset.

Authors:  Marc Veldhoen; Catherine Uyttenhove; Jacques van Snick; Helena Helmby; Astrid Westendorf; Jan Buer; Bruno Martin; Christoph Wilhelm; Brigitta Stockinger
Journal:  Nat Immunol       Date:  2008-10-19       Impact factor: 25.606

10.  IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3.

Authors:  Reiner K W Mailer; Anne-Laure Joly; Sang Liu; Szabolcs Elias; Jesper Tegner; John Andersson
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

View more
  118 in total

Review 1.  The role of Th17 cells in the pathophysiology of pregnancy and perinatal mood and anxiety disorders.

Authors:  Lauren M Osborne; Amitoj Brar; Sabra L Klein
Journal:  Brain Behav Immun       Date:  2018-11-19       Impact factor: 7.217

2.  Increased circulating regulatory T cells in medicated people with schizophrenia.

Authors:  Deanna L Kelly; Xin Li; Catherine Kilday; Stephanie Feldman; Sarah Clark; Fang Liu; Robert W Buchanan; Leonardo H Tonelli
Journal:  Psychiatry Res       Date:  2018-09-05       Impact factor: 3.222

3.  Mechanistic insights into cancer immunity and immunotherapy.

Authors:  Weiping Zou
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

Review 4.  The role of transforming growth factor β in T helper 17 differentiation.

Authors:  Song Zhang
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

5.  CD226 attenuates Treg suppressive capacity via CTLA-4 and TIGIT during EAE.

Authors:  Ning Wang; Shuang Liang; Jingyi Jin; Liang Fang; Qianli Ma; Xian Wang; Yun Song; Lihua Chen
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 6.  Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation.

Authors:  Shabnam Shalapour; Michael Karin
Journal:  Immunity       Date:  2019-07-16       Impact factor: 31.745

7.  Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease.

Authors:  Chiara Donadei; Andrea Angeletti; Chiara Cantarelli; Vivette D D'Agati; Gaetano La Manna; Enrico Fiaccadori; Julian K Horwitz; Huabao Xiong; Chiara Guglielmo; Susan Hartzell; Joren C Madsen; Umberto Maggiore; Peter S Heeger; Paolo Cravedi
Journal:  JCI Insight       Date:  2019-04-23

Review 8.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

9.  IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors.

Authors:  Hannah M Knochelmann; Connor J Dwyer; Aubrey S Smith; Jacob S Bowers; Megan M Wyatt; Michelle H Nelson; Guillermo O Rangel Rivera; Joshua D Horton; Carsten Krieg; Kent Armeson; Gregory B Lesinski; Mark P Rubinstein; Zihai Li; Chrystal M Paulos
Journal:  Cancer Res       Date:  2020-06-19       Impact factor: 12.701

10.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.